4-Mar-2025 7:00 AM CST - Business Wire Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that u
3-Mar-2025 7:00 AM CST - Business Wire Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business highlights. Closing out 2024 with positive Phase 2 CANYON results, completing enrollment in GRAND CANYON and advancing CIRRUS-HCM, we are well positioned in 2025 across our muscular dystrophy and cardiovascular portfolio, said Kevin Koch, Ph.D., President and Chief Exe
13-Jan-2025 7:00 AM CST - Business Wire Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the Annual J.P. Morgan Healthcare Conference. We were pleased with our progress in 2024 as we advanced our drug pipeline and have great momentum heading into 2025. With positive Phase 2 results
7-Jan-2025 7:00 AM CST - Business Wire Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 pm PT (4:30 pm ET). The discussion will include updates on its cardiovascular and muscular dystrophy programs and 2025 key milestones. The presentation will be webcast live; a link for the
16-Dec-2024 5:00 AM CST - Business Wire Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. The trial met its primary endpoint of change from baseline in CK. C
26-Nov-2024 5:00 AM CST - Business Wire Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that
7-Nov-2024 7:00 AM CST - Business Wire Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. We continue to make strong progress on our cardiac and skeletal muscle programs, said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. Based on the strength of clinical and preclinical data to-date, we are treating patients with obstructive and non-o
4-Mar-2025 7:00 AM CST - Business Wire Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that u
3-Mar-2025 7:00 AM CST - Business Wire Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business highlights. Closing out 2024 with positive Phase 2 CANYON results, completing enrollment in GRAND CANYON and advancing CIRRUS-HCM, we are well positioned in 2025 across our muscular dystrophy and cardiovascular portfolio, said Kevin Koch, Ph.D., President and Chief Exe
13-Jan-2025 7:00 AM CST - Business Wire Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the Annual J.P. Morgan Healthcare Conference. We were pleased with our progress in 2024 as we advanced our drug pipeline and have great momentum heading into 2025. With positive Phase 2 results
7-Jan-2025 7:00 AM CST - Business Wire Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 pm PT (4:30 pm ET). The discussion will include updates on its cardiovascular and muscular dystrophy programs and 2025 key milestones. The presentation will be webcast live; a link for the
16-Dec-2024 5:00 AM CST - Business Wire Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. The trial met its primary endpoint of change from baseline in CK. C
26-Nov-2024 5:00 AM CST - Business Wire Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that
7-Nov-2024 7:00 AM CST - Business Wire Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. We continue to make strong progress on our cardiac and skeletal muscle programs, said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. Based on the strength of clinical and preclinical data to-date, we are treating patients with obstructive and non-o
